Dechert represented Aquestive Therapeutics Inc. in two transactions aimed at advancing the launch and commercialization of Anaphylm Sublingual Film, a polymer matrix-based epinephrine prodrug designed as a rescue treatment for severe allergic reactions including anaphylaxis.